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Abstract
Background: Treatment with the α-glucosidase inhibitor acarbose increases median lifespan by approximately 20%
in male mice and 5% in females. This longevity extension differs from dietary restriction based on a number of
features, including the relatively small effects on weight and the sex-specificity of the lifespan effect. By inhibiting host
digestion, acarbose increases the flux of starch to the lower digestive system, resulting in changes to the gut
microbiota and their fermentation products. Given the documented health benefits of short-chain fatty acids (SCFAs),
the dominant products of starch fermentation by gut bacteria, this secondary effect of acarbose could contribute to
increased longevity in mice. To explore this hypothesis, we compared the fecal microbiome of mice treated with
acarbose to control mice at three independent study sites.
Results: Microbial communities and the concentrations of SCFAs in the feces of mice treated with acarbose were
notably different from those of control mice. At all three study sites, the bloom of a single bacterial taxon was the
most obvious response to acarbose treatment. The blooming populations were classified to the largely uncultured
Bacteroidales familyMuribaculaceae and were the same taxonomic unit at two of the three sites. Propionate
concentrations in feces were consistently elevated in treated mice, while the concentrations of acetate and butyrate
reflected a dependence on study site. Across all samples,Muribaculaceae abundance was strongly correlated with
propionate and community composition was an important predictor of SCFA concentrations. Cox proportional
hazards regression showed that the fecal concentrations of acetate, butyrate, and propionate were, together,
predictive of mouse longevity even while controlling for sex, site, and acarbose.
Conclusion: We observed a correlation between fecal SCFAs and lifespan in mice, suggesting a role of the gut
microbiota in the longevity-enhancing properties of acarbose. Treatment modulated the taxonomic composition and
fermentation products of the gut microbiome, while the site-dependence of the responses illustrate the challenges
facing reproducibility and interpretation in microbiome studies. These results motivate future studies exploring
manipulation of the gut microbial community and its fermentation products for increased longevity, testing causal
roles of SCFAs in the observed effects of acarbose.
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Background
The Interventions Testing Program (ITP) is a long-
running, well-powered study of longevity enhancing inter-
ventions in genetically heterogeneous mice with identical
protocols replicated at each of three study sites [1]. The
drug acarbose (ACA) has been reproducibly shown in that
study to increase mouse median lifespan with a larger
effect in males than females [2–4]. The largest increase
was found when treatment began at 4 months, 22% in
males and 5% in females [2], but the beneficial effect
was still detectable in mice receiving ACA starting at 16
months [3]. The 90th percentile lifespan, a surrogate for
maximum lifespan also shows benefits of ACA, with sim-
ilar magnitudes in both male and female mice [2]. ACA
is a competitive inhibitor of α-glucosidase and α-amylase,
resulting in delayed intestinal breakdown of starch when
taken with food and reduced postprandial increases in
blood glucose. For these reasons, ACA is prescribed for
the treatment of type 2 diabetes mellitus [5], and has also
been shown to reduce the risk of cardiovascular disease in
that population [6].
It is unclear whether the pathways by which ACA
extends longevity in mice overlap with those affected by
dietary restriction (DR), but several observations have
suggested critical differences [2].Weight loss in ACAmice
was more dramatic in females than in males, while the
longevity effect is much stronger inmales. By contrast, DR
effects both weight and lifespan similarly in both sexes.
Likewise, the response of fasting hormone FGF21 to ACA
treatment was opposite in direction from that induced
by DR. In female mice alone, ACA blocked age-related
changes in spontaneous physical activity, while DR leads
to increases in activity in both sexes. It is therefore jus-
tified to suspect that the effects of ACA on longevity are
due to pathways distinct from DR.
Besides reducing the absorption of glucose from starch,
inhibition of host enzymes by ACA results in increased
flow of polysaccharide substrate to the lower digestive sys-
tem [7], approximately mimicking the effects of fiber con-
sumption. ACA has been shown to raise the concentration
of starch in stool [7, 8], and the observed increased excre-
tion of hydrogen in breath [9–13] demonstrates that at
least some of this substrate is fermented by the gut micro-
biota. The major byproducts of polysaccharide fermenta-
tion in the gut are hydrogen, CO2, and short-chain fatty
acids (SCFAs), in particular acetate, butyrate, and propi-
onate. Unsurprisingly, ACA treatment has been observed
to increase acetate concentrations in human feces [14]
and serum [15], as well as concentrations in portal blood
and total amounts in rodent cecal contents [7]. Likewise,
in some studies, ACA increased butyrate concentrations
in human feces [8, 13, 16] and serum [15]. ACA also
increased propionate concentrations in rat portal blood
and total amount in cecal contents [7], as well as total
output in feces in humans [14]. These changes were pre-
sumably due to changes in the activity and composition
of microbial fermenters in the lower gut. Indeed, ACA
was found to modulate the composition of the fecal bac-
terial community in prediabetic humans [17], and both
increase the SCFA production potential inferred from
metagenomes and lower fecal pH [18].
Impacts of ACA on microbial fermentation products
are of particular interest because SCFAs produced in the
gut are known to affect host physiology, with a variety
of health effects associated with butyrate and propionate.
The role of these microbial fermentation products in
host health is reviewed in [19] and [20], and summarized
briefly here. Although butyrate and propionate are pri-
marily consumed by the gut epithelium and liver, respec-
tively, they are nonetheless detectable in peripheral blood,
and acetate can circulate at substantially higher concen-
trations [21]. Four G-protein coupled receptors have been
shown to respond to SCFAs with varying levels of speci-
ficity: FFAR2, FFAR3, HCA2, and OLFR78. All except
OLFR78 are expressed in colonic epithelial cells, and each
is expressed in a variety of other tissues throughout the
body. Similarly, both butyrate and propionate act as his-
tone deacetylase inhibitors which could have broad effects
on gene expression through modulation of chromatin
structure. In total, these pathways contribute to regulation
of cellular proliferation, inflammation, and energy home-
ostasis, among other processes. The effects of ACA on
fermentation products in the gut may, therefore, modulate
its overall effects on host physiology.
Despite theoretical expectations and suggestive empir-
ical results in other animal models, no study has looked
for direct evidence that some of the longevity enhanc-
ing effects of ACA in mice are mediated by the gut
microbiota and the SCFAs produced during fermenta-
tion. Here we test four predictions of that hypothesis: (1)
ACA reproducibly modulates bacterial community com-
position; (2) the concentrations of SCFAs are increased in
ACA-treated mice; (3) community structure is correlated
with SCFAs and other metabolites in both control and
treated mice; and (4) SCFA concentrations are predictive
of lifespan. Fecal samples were analyzed from control and
ACA treated mice enrolled in the ITP protocol at three,
independent study sites.
Results
Study population
Sampled mice are representative of an underlying study
population that recapitulates the previously observed sex-
specific longevity effects of ACA. Across all three sites,
ACA increased the median male survival of the under-
lying study population by 17% from 830 to 975 days
(log-rank test P < 0.001, see Fig. 1). Female median sur-
vival increased 5% from 889 to 931 days (P = 0.003).
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Fig. 1 Survival curves of sampled cohort. Survival curves for mice fed a control diet (blue lines) or mice fed the same diet containing ACA (gold) at
each of three sites: TJL, UM, and UT. Median longevity for each group of mice is indicated by a dashed vertical line. Grey circles indicate the age at
death for each of the sampled mice at UM and UT. The number of samples summarized by each line is described in Table. 1
These results are consistent with the increased longevity
due to ACA previously reported [2]. Fecal samples from
48 mice at each of three study sites—The Jackson Lab-
oratory (TJL), the University of Michigan (UM), and the
University of Texas Health Science Center at San Anto-
nio (UT)—were collected between 762 and 973 days of
age with a balanced factorial design over sex and treat-
ment group. While having samples collected at the same
age for all mice might have reduced some of the observed
variability, and this does represent one limitation of the
study, the collection window is narrow relative to other
biological variation of the mice. For example, the standard
deviation in the longevity of mice sampled for this study
was 112 days, versus a standard deviation of 50 days for
age at sample collection. Visual inspection of the over-
all survival curves (Fig. 1) confirmed that the longevity of
mice sampled for microbiome analyses at UM andUTwas
representative of the other, surviving, unsampled mice.
The total number of mice from which microbiome or
longevity data were obtained is summarized in Table 1.
Samples from TJL were not matched to individual mice
and longevity measures are therefore not available for the
subset described here.
Differences in fecal community in ACA-treated mice
ACA-treated mice had a substantially different microbial
community composition from control mice at all three
study sites. In a multivariate analysis of variance on site,
sex, and treatment using Bray-Curtis dissimilarities and
including all two-way interactions, significant effects were
found for treatment (partial r2 = 9.6%, PERMANOVA
P < 0.001) and site (partial r2 = 16.4%, P < 0.001), as
Table 1 Number of mice sampled
Treatment Site Sex Taxonomic Metabolite Longevitya
Control TJL Female 12 12 96b
ACA TJL Female 11 10c 48b
Control TJL Male 12 12 102b
ACA TJL Male 12 12 54b
Control UM Female 12 12 96
ACA UM Female 12 11c 48
Control UM Male 12 12 108
ACA UM Male 12 12 54
Control UT Female 12 12 96
ACA UT Female 12 12 48
Control UT Male 12 11c 102
ACA UT Male 12 12 54
aMicrobiome data were not matched to longevity for mice at TJL
bLongevity data were compiled for both sampled and unsampled mice in the ITP
cohort
cMetabolite data were not compiled for one mouse from each of three groups due
to technical irregularities
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well as their interaction (partial r2 = 3.4%, P < 0.001).
These statistical results reflect the separation apparent in
a principal coordinates ordination (see Fig. 2). A much
smaller but still significant effect of sex (partial r2 = 1.0%,
P = 0.014) was also identified, but there was no interac-
tion between sex and treatment (P = 0.344). Despite the
unbalanced design, significance of the PERMANOVAwas
not affected by changing the order of predictors. Based
on a test of multivariate homogeneity of variances, dis-
persion differed between sites (PERMDISP P < 0.001)
and sexes (P = 0.023), which may bias the PERMANOVA
results, but did not differ between treatments (P = 0.425).
The small effect of sex and the lack of significant sex-
by-treatment interaction effects suggest that community
composition itself, at the level of overall diversity, is not
directly responsible for differential effects of ACA on
longevity in male and female mice. However, the sub-
stantial differences in community composition due to
treatment, while not surprising, suggests that the effects
of ACA on themicrobiome have the potential to modulate
host health.
The fecal bacterial community in control mice was dom-
inated by a handful of bacterial families (see Table 2 for
details). Across control mice at all three sites, a median of
30% of sequences were classified as members of the largely
uncultured family Muribaculaceae—historically called
the S24-7—belonging to the phylum Bacteroidetes [22].
Other abundant families included the Lachnospiraceae
(27%), Ruminococcaceae (14%), Lactobacillaceae (9%), and
Erysipelotrichaceae (1%), all of which are classified in
the phylum Firmicutes. More than 99.99% of sequences
across all mice were classified at or below the family level.
More detailed classification of sequences is provided in
Additional file 1.
At a 97% sequence similarity cutoff, 271 operational
taxonomic units (OTUs) had a mean relative abundance
across all samples of greater than 0.01% and an incidence
of greater than 5%. Of these, the relative abundance of
113 OTUs differed between treated and control mice, cor-
recting for a false discovery rate (FDR) of 5%. Together,
these OTUs account for a median relative abundance of
54% across both control and treated mice. OTUs differ-
ing between sexes or reflecting an interaction between sex
and treatment were a substantially less abundant. 5 OTUs
were identified after FDR correction that differed signif-
icantly in relative abundance between male and female
mice, accounting for a median, summed relative abun-
dance of 6%. 7 OTUs were found to be subject to an
interaction between treatment and sex, with a median rel-
ative abundances of 2%. Details of OTUs responsive to
treatment, sex, and a treatment-by-sex interaction have
been included in Additional file 1.
Differences between control and ACA mice at TJL and
UM were dominated by the increased abundance of a sin-
gle OTU, OTU-1, which had a median relative abundance
of 7.7% in control mice compared to 28.8% in ACA mice
at TJL (Mann-Whitney U test P < 0.001), and 10.4% com-
pared to 39.0% at UM (P < 0.001) (see Fig. 3). At UT,
OTU-1 was higher in ACA-treated mice—a median of
5.4% and 11.0% in control and treated mice, respectively—
but this increase was not statistically significant (P =
0.344). Instead, a different OTU, designated OTU-4, was
A B C
Fig. 2Microbial community composition. Fecal bacterial community composition in mice fed the control diet (circles) or the same diet
supplemented with ACA (triangles). The two dominant principal coordinates, based on Bray-Curtis dissimilarities among community profiles, are
plotted, and percent of variation explained by each is indicated in parentheses on the axes. The location of points in each panel is identical. Markers
denote whether mice were treated (triangles) or controls (circles). In (a) points are colored by treatment: control mice (blue) and ACA-treated (gold),
in (b) points are colored by site: TJL (bright pink), UM (blue), and UT (green), and in (c) points are colored by sex: male (light blue) and female (pink).
The number of samples depicted in each panel is described in Table 1
Smith et al. BMCMicrobiology          (2019) 19:130 Page 5 of 16
Table 2 Abundance of common bacterial families
Family % controla % ACAa ACA : controlb
Muribaculaceae 30.4 (21.5, 43.3) 48.1** (35.3, 61.8) 1.8**
Lachnospiraceae 26.6 (16.3, 41.6) 23.9† (9.6, 37.4) 1.3
Ruminococcaceae 14.2 (9.0, 19.0) 11.6* (6.9, 15.6) 1.1
Lactobacillaceae 9.5 (1.2, 17.0) 2.6* (1.0, 8.2) 0.31*
Erysipelotrichaceae 1.4 (0.3, 6.2) 0.5* (0.2, 2.2) 0.42†
aMedian and interquartile range of the relative abundance of the top five most
abundant bacterial families in control and ACA-treated mice
bthe ratio of median spike-adjusted abundances in ACA-treated mice versus control
mice
†P < 0.1 via Mann Whitney U test
*P < 0.05
**P < 0.001
strongly affected by ACA treatment at UT, with a median
relative abundance of 6.3% in control mice that increased
to 25.6% in ACA-treated mice (P = 0.007). OTU-4 was
nearly absent at TJL and UM, with only one mouse out
of 95 having a relative abundance above 0.1%, compared
to 39 out of 48 mice at UT. Differences in abundance
between sexes were not observed for OTU-1 at TJL or
UM, but at UT results were suggestive of an increased
abundance of OTU-1 in females (P = 0.076) and an
increased abundance of OTU-4 in males (P = 0.060).
Interestingly, their combined abundance did not differ
betweenmales and females (P = 0.344) at UT. BothOTU-
1 and OTU-4 were classified as members of theMuribac-
ulaceae, and subsequent phylogenetic analysis confirmed
this placement (see Additional file 2). OTU-1 and OTU-
4 are approximately 90% identical to each other and to
the most closely related cultivar (DSM-28989) over the V4
hypervariable region of the 16S rRNA gene. These OTUs
are notable both for their high abundance overall, as well
as the large difference between control and ACA-treated
mice. It is surprising that OTU-4 is common and differ-
entially abundant at UT, while remaining rare at both of
the other sites, suggesting that local community composi-
tion modulates the effects of ACA. While OTU-1 is made
up of multiple unique sequences, the composition within
the OTU does not differ substantially with ACA treatment
(see Additional file 3).
The increased relative abundance of OTU-1 and OTU-
4 in mice treated with ACA appears to be due to greater
abundance of these sequences, and is not explained solely
by a decrease in other groups. The abundance of taxa
in control and treated mice was compared based on the
recovery of spiked-in standard relative to the sequence
of interest. The median combined spike-adjusted abun-
dance of 16S rRNA gene copies from OTU-1 and OTU-4
was 4.3 times greater per gram of feces in ACA-treated
mice compared to controls (Mann-Whitney U test P <
0.001), suggesting a corresponding increase in population
density.
While OTU-1 and OTU-4 are classified to the same
family and are similarly affected by ACA, other OTUs in
theMuribaculaceae have decreased abundance in treated
mice. The combined relative abundance of all other OTUs
Fig. 3 Abundance of dominant OTUs. Relative abundance of the 16S rRNA gene from two OTUs classified as belonging to the family
Muribaculaceae, abundant in ACA-treated mice. Points in each panel correspond with samples collected from individual mice at each of three
replicate study sites. Samples were obtained from mice fed either the control diet (blue, labeled ‘-’) or the same diet supplemented with ACA (gold,
labeled ‘+’). Markers indicate the sex of the mouse: male (triangle) or female (circle). The number of samples illustrated in each panel is described in
Table. 1. Boxes span the interquartile range and the internal line indicates the median. (*: P < 0.05, **: P < 0.001 by Mann-Whitney U test)
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in the family—excluding OTU-1 and OTU-4—was 8.3%
in treated mice versus 16.8% of sequences in control mice
(Mann-Whitney U test P < 0.001). The median combined
spike-adjusted abundance of all other Muribaculaceae
OTUs was 0.5 times the median in control mice (P =
0.001), suggesting a decrease in the population density of
these taxa. This is consistent with competition between
OTUs in this family.
Three of the five most abundant families all exhibit
decreased relative abundance in ACA treated mice
(see Table 2). However, the large increase in abundance
of OTU-1 and OTU-4 suggests that some changes in the
relative abundance of other taxa may be the result of
compositional effects, rather than decreased density. For
instance, although the relative abundance of Ruminococ-
caceaewas lower in ACA-treated mice, the spike-adjusted
abundance was little changed (P = 0.327), emphasiz-
ing the value of this complementary analysis. Conversely,
decreased relative abundance was matched by decreased
spike-adjusted abundance for both the Lactobacillaceae
(P = 0.014) and the Erysipelotrichaceae (P = 0.063).
ACA-treated mice exhibited decreased fecal commu-
nity diversity. The median Chao1 richness estimate was
decreased from 229 in control mice to 199 in treated mice
(Mann-Whitney U test P < 0.001). The Simpson’s even-
ness index was also lower in ACAmice: 0.044 versus 0.075
in controls (P < 0.001). This reduced richness and even-
ness is not surprising given the much greater abundance
of a single OTU in treatedmice at each site. To understand
changes in diversity while controlling for compositional
effects, we measured the effect of ACA ignoring counts
for OTU-1 and OTU-4. While Simpson’s evenness was
not decreased by treatment in this fraction of the com-
munity (P = 0.26), the Chao1 richness—subsampling
to equal counts after partitioning—was decreased (P =
0.005), suggesting that the bloom of OTU-1 and OTU-4
may have, in fact, resulted in the local extinction of rare
community members.
Changes in fecal metabolite concentrations
The effects of long-term ACA treatment on fecal metabo-
lite profiles was variable across study sites, but with
increased concentrations of propionate at all three
(see Fig. 4). Consistent with the expected increase in starch
in the lower gut, glucose concentrations were higher in
ACA-treated mice at UM (from a median of 6.1 μmols/g
in control mice to 12.9 in treated mice, Mann-Whitney
U test P < 0.001), and UT (2.8 to 9.1, P < 0.001). At
TJL, while the statistical test did not surpass the signif-
icance threshold, there was also an observed increase in
glucose concentrations (6.6 to 9.1, P = 0.069). However,
this presumed increase in fermentable substrate did not
result in increased total SCFA—here defined as the sum
of acetate, butyrate, and propionate concentrations—at
either TJL (22.4 to 18.8, P = 0.443), or UM (19.1 to 24.8,
P = 0.092). Interestingly, total SCFA was sharply higher
in ACA treated mice at UT alone (17.7 to 31.9, P < 0.001).
This same pattern of variation across sites was found in
the effects of ACA on fecal acetate and butyrate concen-
trations, where statistically significant increases were only
found at UT (acetate: P = 0.003, butyrate: P < 0.001),
but not at either of the other two sites. Fecal propionate
concentrations, on the other hand, were elevated in ACA
mice at all three study sites, from a median of 0.93 to 1.9
at TJL (P = 0.001), from 1.1 to 2.5 at UM (P < 0.001), and
from 1.9 to 2.9 at UT (P = 0.008).
The consistent increase in fecal propionate wasmatched
by consistently lower concentrations of one of its
metabolic precursors, succinate, at all three sites, from
2.8 in control to 1.5 in ACA-treated mice at TJL (P =
0.009), from 3.0 to 1.2 at UM (P < 0.001), and from
3.1 to 2.1 at UT (P = 0.022). Median lactate concen-
trations were also lower in ACA treated mice, although
this was only statistically significant at UT (P = 0.002).
It is surprising that these fermentation intermediates are
reduced, given the expected increase in available polysac-
charide. It is possible that their concentrations reflect
greater consumption in downstream pathways, or perhaps
ACA directly inhibits the metabolism and growth of rele-
vant bacteria; such effects have been previously reported
for in vitro fermentations of starch with human fecal slur-
ries [8]. Concentrations of formate, valerate, isobutyrate,
and isovalerate were generally below the detection limit.
Fresh pellet weight was increased from a median of 36 to
74 mg (P < 0.001).
Given the inconsistant observation of changes in
metabolite concentrations with ACA across study sites,
we tested for treatment-by-site interaction effect using
an ANOVA framework, with log-transformed metabo-
lite concentrations to better accommodate distributional
assumptions. Using this approach, significant interactions
were found for glucose (P = 0.005), and acetate (P =
0.044), and results were suggestive for succinate (P =
0.069), butyrate (P = 0.071), and total SCFA (P = 0.053).
Treatment-by-site interaction effects were not found for
lactate (P = 0.266) or propionate (P = 0.542).
Differences in SCFAs between sexes are particularly
interesting given the greater longevity effects of ACA
in male mice. In a log-linear model that included terms
for site, sex, and treatment, as well as all other two-way
interactions, including a treatment-by-sex interaction sig-
nificantly improved the fit of the model for propionate
(LRT P = 0.020), but not for butyrate or acetate. This
interaction results in a larger difference in propionate con-
centrations for male mice (from an overall median of 1.4
μmols/g in control mice to 2.7 in ACA) than for female
mice (from 1.0 to 1.9) with ACA treatment. The sig-
nificance of the interaction term was not corrected for
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Fig. 4 Fecal metabolites. Concentrations of metabolites in feces obtained from mice fed either the control diet (open circles) or the same diet
supplemented with ACA (solid circles), at each of three study sites: TJL (bright pink), UM (blue), and UT (green). Lines span the interquartile range
and the circle indicates the median. The summed concentration of acetate, butyrate, and propionate is plotted as “total SCFA”. The number of
samples summarized in each panel is described in Table. 1. Symbols indicate the significance of a Mann-Whitney U test comparing control to
ACA-treated mice. († : P < 0.1, ∗ : P < 0.05, ∗∗ : P < 0.001)
multiple testing, and therefore additional studies would
greatly increase our confidence in this result.
Community predictors of fecal SCFA concentrations
As both community composition and the effects of
ACA on metabolite concentrations in feces varied greatly
between study sites, we explored the relationship between
microbial abundance andmetabolite concentration. Com-
munity composition was correlated with metabolite con-
centrations in both control and ACA-treated mice.
Numerous strong correlations were detected between the
spike-adjusted abundance of 16S rRNA copies from the
most common bacterial families and the concentrations of
SCFAs and lactate. Notably, Muribaculaceae abundance
was particularly strongly correlated with propionate con-
centrations in both control (Spearman’s ρ = 0.36, P =
0.002; see Fig. 5) and ACA mice (ρ = 0.64, P < 0.001).
Likewise, Lachnospiraceae were correlated with butyrate
(ρ = 0.61 in control and 0.77 in ACA, P < 0.001 for
both), and Lactobacillaceae with lactate concentrations
(ρ = 0.63 in control and 0.67 in ACA, P < 0.001 for
both). Strikingly, concentrations of acetate and butyrate
were especially correlated with each other (ρ = 0.67 in
control and 0.80 in ACA, P < 0.001 for both). What’s
more, all of these correlations were found in treated mice
even when independently tested at each of the three sites,
suggesting that they cannot be explained by simple associ-
ations betweenmetabolite concentrations and community
composition at the site level.
Although our study was not an unambiguous test, these
results support the hypothesis that the fecal metabolite
response to treatment is dependent on the population
density of relevant microbes in the gut community. Sim-
ilarly, environmental and host factors that promote or
inhibit the growth of particular community members
would be expected to modulate the response.
To identify key players in these associations, we exam-
ined the relationship between metabolite concentrations
and the spike-adjusted abundances of OTUs. Based on a
least absolute shrinkage and selection operator (LASSO)
regression analysis, the abundances of a number of OTUs
can be used to predict concentrations of propionate,
butyrate, acetate, and lactate even after accounting for
treatment, sex, and study site. Consistent with the correla-
tions found betweenMuribaculaceae abundance and pro-
pionate, OTU-1 and OTU-4 were identified as predictors
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Fig. 5Microbiota/metabolite correlations. Correlations among metabolite concentrations in feces and family level, spike-adjusted 16S rRNA gene
abundances. Points correspond with samples collected from individual mice and colors indicate whether they were obtained from mice fed the
control diet (blue) or the same diet supplemented with ACA (gold). Markers indicate the site where the mouse was housed: TJL (diamond), UM
(circle), or UT (triangle). Metabolite concentrations are reported normalized to feces wet weight, and abundances are in spike-equivalent units.
Values are on a linear scale between 0 and the subsequent tick label, above which, points are plotted logarithmically. The number of samples
illustrated in each panel is described in Table 1
of increased propionate, along with a third taxon, OTU-
5, also classified as a member of the family. For both
butyrate and acetate, OTUs classified as members of both
the Lachnospiraceae and Ruminococcaceae were most
predictive of increased concentrations. Unsurprisingly,
the most abundant OTU classified as a member of the
Lactobacillaceae, OTU-2, was found to be highly pre-
dictive of increased lactate. However, 8 OTUs were also
associated with decreased lactate concentrations, most
of which were among those associated with increased
butyrate and acetate. Among other explanations, this is
consistent with these taxa either being inhibited by lactate
or being lactate utilizers, which are likely to be producing
SCFAs as secondary fermentation products. Regression
coefficients for each metabolite are included in Additional
file 1. Overall, results were both consistent with a priori
expectations, and useful for generating hypotheses about
which taxa might be associated with the generation of
fermentation products.
Fecal SCFA concentrations as predictors of longevity
Given the documented health benefits of SCFAs in the
gut (reviewed in [19]) and their increased levels in ACA-
treated mice, we tested the relationship between the
acetate, butyrate, and propionate concentrations in feces,
and the lifespan of individual mice. Lifespans of fecal
donors were not available for mice at TJL, so survival
analyses were carried out only with UM and UT mice,
and effect sizes are reported for SCFAs as standardized
hazard ratios (HRs). Due to the reduced number of mice
sampled for this study, data were pooled across sexes
and sites. The shared effects of the design parameters—
treatment, sex, and study site—on both SCFAs and
longevity, were accounted for by including terms for these
covariates as well as their two and three-way interactions.
Analyses reinforcing our interpretations are discussed in
Additional file 4. Tested individually against this nullmodel,
an association between longevity and propionate was
found (standardized HR of 0.727, P = 0.031), but no
relationship was observed with butyrate (P = 0.240) or
acetate (P = 0.742). However, when the model was fit
with all three SCFAs simultaneously, each was found to be
associated with longevity (P = 0.012, 0.030, 0.042 for pro-
pionate, butyrate, and acetate, respectively). Coefficients
for SCFA covariates in this full model suggest a posi-
tive association with longevity for both propionate and
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butyrate (standardized HR of 0.674 and 0.586, respec-
tively). Interestingly, a negative association was foundwith
acetate (standardized HR of 1.576) using this model. The
discrepancy between this result and the lack of associa-
tion when butyrate and acetate are each tested alone likely
reflects the strong positive correlation between acetate
and butyrate concentrations, masking their individual,
opposing associations with longevity. The overall fit of the
full model was improved compared to the null model with
only design covariates (likelihood ratio test, P = 0.023).
Discussion
ACA, by inhibiting the enzymes responsible for starch
degradation in the small intestine, is expected to increase
the availability of this polysaccharide to the microbiome.
The resulting increase in SCFA production may con-
tribute to the effects of ACA on health. Despite previous
observations in humans and rats that ACA results in sub-
stantial changes to the community structure [8, 17] and
fermentation products [7, 8, 13, 16] of the gut micro-
biota, a link between these effects on the microbiome
and longevity has not been established. Here we present
one of the first studies to combine bacterial community
surveys with measurement of fecal metabolites in ACA
treated mice (with the notable exception of [23]), as well
as the first to pair these data with lifespan, allowing us to
explore the role of the microbiome in increased longevity.
By considering mice at three parallel study sites, we are
also able to account for variation in the composition and
response of the gut microbiota and its impact on study
reproducibility.
Our results support all four predictions that we set out
to test: ACA was found to affect both (1) the composition
of bacterial communities and (2) SCFAs in mouse feces,
(3) the abundances of individual taxonomic groups were
correlated with concentrations of fermentation products,
and (4) the concentrations of fecal SCFAs were associated
with variation in mouse longevity.
While it is unsurprising that an increased flux of starch
to the large intestine affected the gut microbiota and their
fermentation products, the specific impacts could not be
easily predicted, especially since ACA can also inhibit bac-
terial enzymes, and this can be variable across taxa [24].
The increased relative abundance in ACA-treated mice of
the dominant OTU—OTU-1 at UM and TJL and OTU-
4 at UT—was dramatic: one or the other was increased
approximately 4-fold at all three sites and in multiple sam-
ples more than half of sequences belonged to these OTUs.
A cursory BLAST search reveals that sequences identi-
cal to OTU-1 have been previously recovered in published
studies (e.g. [25] and [26]); in [27] the sequence was found
at high relative abundance in the brains of mice that had
undergone sepsis. It was notable that OTU-1 did not
respond to ACA at UT, while its increased abundance
was so striking at UM and TJL. Our results appear to
constrain the potential explanations for this observation.
OTU-1 was present and abundant at all three sites; The
abundance in control mice was lowest at UT, although the
median there was still greater than 5%. While it is not
possible with the data presented here to rule out genomic
differences of OTU-1 among sites, a similar composition
of unique 16S rRNA gene sequences made up this clus-
ter at all three (see Additional file 3). On the other hand,
OTU-4 was at very low abundance, with no reads in a
majority of samples, at UM and TJL where OTU-1 did
respond to ACA. These results suggest that both OTUs
respond to ACA in the same way, with OTU-4, when it
is sufficiently abundant, inhibiting the response of OTU-
1, potentially through resource competition. Both OTUs
are in the same family, the Muribaculaceae, but are not
the same species or genus by the traditional similarity
thresholds, sharing only 90% identity over the sequenced
fragment. The differential response of these OTUs among
sites illustrates the importance of each site’s local “meta-
community” in determining the microbial community’s
response to environmental perturbations.
Pronounced differences in the resident microbial com-
munities of different hosts may contribute to challenges in
translating results from mice and other model organisms
to humans. A comparison of bacterial community com-
position in feces in prediabetic people before and during
a 4-week ACA treatment period did not reveal changes
of the magnitude reported here [17], although this may
reflect the limited duration of treatment. Interestingly,
in that study Lactobacillaceae abundance increased with
ACA, while we observed this family to be depleted in
treated mice. The abundance of the Muribaculaceae was
not reported. Although this family is common in mice
and have been previously shown to respond to diet, the
clade is substantially less abundant in most human sam-
ples [28]. However, the prevalence of Muribaculaceae
may be under-reported in the literature, as the Riboso-
mal Database Project [29] does not include the family and
classification using this database assigns sequences to the
Porphyromonadaceae instead [30, 31]. Historically, two
other names have also been used for this clade: the “S24-7”
(from an early environmental clone [32]), and “Candi-
datus Homeothermaceae” (proposed in [28]). While the
initial isolation of Muribaculum intestinale YL27 [22],
and subsequently five additional strains [31], has begun
to explore this largely uncharacterized clade, additional
cultivars will be vital for understanding the function and
ecology of the family. Nonetheless, genomes assembled
from metagenomes suggest that populations of Muribac-
ulaceae are equipped with fermentation pathways to pro-
duce succinate, acetate, and propionate [28], and that the
family is composed of metabolic guilds, each specializing
on the degradation of particular types of polysaccharides:
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plant glycans, host glycans, and α-glucans [28, 31]. This
suggests that the Muribaculaceae may occupy a similar
set of niches in mice as do Bacteroides species in humans.
TheMuribaculaceae and Bacteroides are both in the order
Bacteroidales. Bacteroides also specialize in the fermenta-
tion of polysaccharides [33], and at least some of the most
common species in the human gut are known to produce
succinate, acetate, and propionate from the fermenta-
tion of polysaccharides [19, 34–36]. Unlike the patterns
observed here forMuribaculaceae in mice, the abundance
ofBacteroides decreased with ACA treatment in one study
in humans [17], suggesting that the microbially mediated
effects of ACA may fundamentally differ between these
hosts.
Besides hypotheses based on genome content, the cor-
relation between total Muribaculaceae abundance and
propionate concentrations and the specific association
withOTU-1 andOTU-4 found in the LASSO analysis sug-
gest that both OTUs, and perhaps other Muribaculaceae
species in this study, ferment starch to propionate. This
also supports the hypothesis, discussed above, that both
OTUs occupy overlapping niches. Although increased
butyrate concentrations have been frequently reported
with ACA treatment [7, 8, 13, 15, 16, 23], elevated con-
centrations of propionate have been observed in just one
previous study using portal blood in rats [7]. Studies in
humans have instead found decreased or no change in
fecal [8, 13, 14] or serum [15] propionate concentrations
with ACA. Decreased propionate has been attributed to
preferential production of butyrate from starch fermen-
tation [37, 38] or inhibition of propiogenic bacteria by
ACA [8]. Our observation of increased propionate was
robust and reproduced at all three sites. Interestingly, in
the only other study to pair SCFA measurements with
taxonomic survey results, which also failed to find a signif-
icant increase in propionate, the relative abundance of the
Muribaculaceae was decreased as well [23]. If these con-
flicting findings reflects both the greater initial abundance
and enrichment in our study of the Muribaculaceae—
especially OTU-1 and OTU-4—it demonstrates the value
of measuring both community composition and metabo-
lite concentrations in the same samples.
Intriguingly, the Muribaculaceae have also been
observed to be enriched in mice receiving fecal trans-
plants from donor mice on calorie restricted diets, and
metabolic improvements were also observed in recipients
[39]. Likewise, the response of the in situ bacterial com-
munity suggests a possible role of the microbiome in the
increased longevity of calorie restriced mice [40].
SCFAs are commonly suggested to act as intermedi-
aries between the gutmicrobiota and host physiology [19].
While our study was not designed to provide a causal
test of effects of SCFAs on longevity, and the power of
our analysis was limited, a statistical association between
SCFA concentrations and mouse lifespan supports an
interpretation that is consistent with an extensive liter-
ature on the health benefits of butyrate and propionate
[19]. The positive associations with propionate could,
for instance, be due to FFAR2 dependent regulation of
inflammation [41, 42]. Likewise, both butyrate and pro-
pionate activate FFAR3—which can result in increased
secretion of PYY and GLP-1 [43, 44] with implications for
glucose homeostasis [45]—and inhibit histone deacety-
lases [46], with downstream effects on both inflammation
[47] and carcinogenesis [48]. Interestingly, treatment with
the polysaccharide inulin, which increases fecal SCFA
concentrations in mice [49], was also found in one study
to increase survival in rats [50]. That SCFA concentra-
tions were associated with longevity above and beyond the
effects of ACA, study site, and sex, further supports a role
of the microbiota and their metabolites in the longevity
enhancing effects of ACA treatment.
It is somewhat surprising, however, that a single fecal
sample taken, in some cases, several months before death,
could be predictive of longevity. The association reported
here could reflect other, unmeasured, changes in the
gut microbiome or host physiology. Concentrations of
metabolites in feces are an integration of both produc-
tion and consumption rates along the length of the lower
gut, and may not reflect host exposure nor the strength
of host physiological response. It is also important to note
that, since all mice in this study at the time of sampling
were of an age close to the median lifespan of control
individuals, the results are only relevant to mechanisms
of aging in late-life and should not be extrapolated to
young mice. While suggestive, the results presented here
are unable to rule out a number of alternative mecha-
nisms whichmay confound our analysis of the relationship
between SCFA concentrations and survival. For instance,
variation in starch digestion between mice could also pro-
duce the observed correlations between host physiology
(through blood glucose regulation) and fecal metabolites,
without any direct causal relationship between the two.
Similarly, changes in the measured fermentation products
may reflect effects of ACA on the concentrations of other,
unmeasured microbial metabolites; luminal polyamine
concentrations, for instance, have been linked to longevity
in mice [51]. Experimental tests of a causal role for micro-
bial products, such as SCFAs, in longevity are challenging,
as they require controlled manipulation of intestinal con-
centrations for the lifetime of a mouse.
It is notable that both community composition and
SCFA concentrations were distinct at each of the
three replicate study sites. Given the robust correla-
tions between bacterial abundance and metabolites, as
well as treatment-by-site interactions in SCFA concentra-
tions, attempting to generalize results from a single study
site would be misguided. Our results suggest that such
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variation can contribute to the challenges in reproducing
and translating results from animal models even in stud-
ies that do not explicitly consider themicrobiome [52–55].
This reinforces the importance of replication and multi-
site studies, and illustrates the value of such designs for
testing the role of the microbiome in outcomes.
Due to the preferential enhancement of longevity by
ACA in male mice we sought to identify aspects of the
gut microbiome that responded differently in male and
female mice (i.e. interaction effects), as these might sug-
gest mechanistic explanations for differences in longevity
effects [2]. While we do not believe that the magnitude
of sex-by-treatment interactions observed for various
aspects of the microbiome were sufficiently pronounced
to fully explain the differential effect of ACA on lifespan,
our search was limited by sample size, variability between
study sites, and the large number of features being tested.
Nonetheless, ACA was found to increase propionate con-
centrations more in male mice than females, a statistically
significant pattern before correction for multiple testing,
and the relative abundance of a handful of OTUs seem to
have also been subject to an interaction.
Mechanisms unrelated to the gutmicrobiome have been
proposed for the effects of ACA on lifespan. Because ACA
reduces the postprandial glucose spike observed in mice
and humans, hypotheses emphasizing the reduction of
harmful effects associated with these transient surges have
been most commonly invoked. Studies of UM-HET3 mice
given ACA from 4 to 9 months of age suggested that mean
daily blood glucose levels are minimally affected, but that
absorption of glucose was both slower and longer last-
ing [2]. Interestingly, fasting insulin level in ACA-treated
males are much lower than those in control males, con-
sistent with an improvement in insulin sensitivity [2].
This reduction was not seen in females, where insulin
levels in controls were lower than in control males and
similar to those in ACA-treated males [2, 56], present-
ing one possible explanation for the stronger longevity
benefit in males. Still, the connection between this modu-
lation of postprandial glucose—with or without improved
insulin sensitivity—and extended longevity is far from
certain.
The work presented here explores a different hypoth-
esis: that health benefits in ACA mice are related to
changes in the activity of microbial communities in the
gut associated with the increased influx of starch, and
possibly attributable to known health effects of micro-
bial metabolites, including SCFAs. Observed changes in
both community composition and fermentation products
due to ACA treatment, along with the statistical associa-
tion between fecal SCFA concentrations and longevity, are
consistent with this hypothesis, and provide a stepping-
stone for future studies. Interestingly, SCFAs themselves
have well documented effects on glucose homeostasis
(reviewed in [57] and [58]). The two explanations are
therefore not mutually exclusive, and the effects of ACA
on longevity may be mediated by both glucose physiology
and microbial activity in the gut.
Conclusions
Here we have tested four predictions of a proposed model
connecting ACA to lifespan via the gut microbiome. We
demonstrate that ACA reproducibly modulates the com-
position of the microbiota, as well as the concentrations of
fermentation products, increasing the abundance of pro-
pionate in particular. In addition, we provide evidence that
the structure of the microbial community is an important
factor in the composition ofmetabolites produced. Finally,
we observe an association between SCFA concentrations
in feces and survival, suggesting a role of the micro-
biome in the life-extending properties of ACA. Together,
these results encourage a new focus on managing the gut
microbiota for host health and longevity.
Methods
Mouse housing and ACA treatment
Mice were bred and housed, and lifespan was assessed as
described in [2]. Briefly, at each of the three study sites,
genetically heterogeneous, UM-HET3, mice were bred by
a four-way cross as previously described in [59], from
CByB6F1/J females and C3D2F1/J males purchased annu-
ally from the Jackson Laboratories. After weaning, mice
were fed LabDiet® (TestDiet Inc.) 5LG6 produced in com-
mon batches for all sites. At 42 days of age, electronic ID
chips were surgically implanted, under isoflurane inhala-
tion anesthesia, and treatment randomly assigned to each
cage housing four mice to a cage for females and three to a
cage for males. ACA-treated mice were fed the same chow
amended with 1000 ppm ACA (Spectrum Chemical Man-
ufacturing Corporation) from 8 months of age onwards.
Mice were transferred every 14 days to fresh, ventilated
cages with water provided in bottles. Colonies at all three
sites were assessed for infectious agents four times each
year, and all tests were negative for the entire duration of
the study. For humane reasons, mice believed to be within
48 h of death were euthanized by CO2 asphyxiation, and
all mice died in this way or from natural causes by the end
of the study.
Sample collection and processing
Fresh fecal pellets were collected directly from mice
between 762 and 973 days of age and frozen at -80°C.
We did not control the time of day at collection. While
differences in age and collection time could have added
variability to SCFA concentrations, both were similarly
distributed for the different treatment groups, so they
are unlikely to confounded our analyses. To eliminate
potential cage effects from co-housed mice [54], samples
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were obtained from no more than one randomly selected
mouse per cage. A total of 144 samples were collected
from 12 male and 12 female mice in both control and
ACA treatment groups at each of the three sites. Sam-
ples were shipped on dry ice and then stored, frozen,
until processing. For approximately the first half of sam-
ples, we extracted the soluble fraction by homogenizing
pellets with 200μL of nuclease-free water. For the remain-
ing samples, we instead used a 1:10 ratio (weight:volume),
with a maximum volume of 1.5 ml. This was found to
improve quantification in higher weight samples. While
SCFA concentration estimates were higher when using
the amended protocol, the order of sample extraction
was fully randomized, so it is unlikely to have biased our
interpretations. Homogenized samples were centrifuged
at 10,000 × g for 10 minutes to separate soluble and
solid fractions. The supernatant was then serially vac-
uum filtered, ultimately through a 0.22 μm filter, before
HPLC analysis. The solid fraction was frozen prior to
DNA extraction. Four samples were excluded from chem-
ical analysis and one from DNA analysis due to technical
irregularities during sample processing.
Prior to DNA extraction, fecal pellet solids were thawed
and, where necessary, subsampled for separate analysis.
To move beyond relative abundance, solids were weighed
and spiked with 10 μL aliquots of prepared Sphingopy-
xis alaskensis strain RB2256—an organism not found
in mouse feces—in order to compare 16S rRNA gene
abundance between samples [60, 61]. The spike was pre-
pared as follows: a 1:200 dilution of a stationary phase
S. alaskensis culture was grown at room temperature
for approximately 44 hours in R2B medium with shak-
ing. This culture was harvested at a final OD420 of 0.72
before being rinsed in PBS and resuspended—5-fold more
concentrated—in 20% glycerol in PBS (v/v). Aliquots of
these cells were stored at -20°C before extraction and
sequencing. Spiked fecal samples were homogenized in
nuclease free water at a ratio of 1:10 (w/v). DNA was
extracted from 150 μL of this mixture using the MoBio
PowerMag Microbiome kit.
Chemical analysis
The chemical composition of samples was assessed on
a Shimadzu HPLC (Shimadzu Scientific Instruments)
equipped with an RID-10A refractive index detector.
30 μL injections were run on an Aminex HPX-87H
column (Bio-Rad Laboratories, Hercules, CA) at 50°C
with 0.01 N H2SO4 mobile phase and a flow rate of
0.6 ml/minute. External standards were run approxi-
mately daily containing acetate, butyrate, formate, glucose,
lactate, propionate, and succinate at 8 concentrations
between 0.1 mM to 20 mM. Due to the complexity of the
chromatogram, the identity and area of retained peaks was
curated manually, assisted by the LC Solutions Software
(Shimadzu Scientific Instruments) Standard curves were
fit using weighted regression (inverse square of the con-
centration), and, for all compounds except propionate,
without an intercept.
16S rRNA gene sequencing and analysis
The V4 hypervariable region of the 16S rRNA gene was
amplified from extracted DNA (as described in [62]), and
sequenced on an Illumina MiSeq platform using a MiSeq
Reagent Kit V2 500 cycles (cat# MS-102-2003). Amplicon
sequences were processed with MOTHUR (version 1.39.4
[63]) using a protocol based on the 16S standard oper-
ating procedures [62]. Scripts to reproduce our analysis
can be found at [64]. After fusing paired reads, quality
trimming, and alignment to the SILVA reference database
(Release 132 downloaded from [65]), the vast major-
ity of 16S rRNA gene sequences were between 244 and
246 bp. Sequences were classified using the method of
Wang et al. [66] as implemented in MOTHUR and with
the SILVA non-redundant database as a reference [67].
We clustered sequences into OTUs using the OptiClust
method [68] at a 97% similarity threshold.We counted and
removed sequences classified as S. alaskensis, the spiked-
in standard, before further analysis. We did not attempt
to assess the exact number of 16S rRNA gene copies
spiked into samples. Instead, spike-adjusted abundance
was defined in units based on the standardized spike
(μL spike equivalents/g sample) and estimated using the
formula:
RelativeAbundance × (TotalEndemicReadCount × SpikeVolume)
(TotalSpikeReadCount × SampleWeight)
Family level abundance was calculated as the summed
abundance of all sequences clustered in OTUs classified
to that family. OTU counts were randomly subsampled
to the minimum number of reads before calculating α-
diversity metrics, but were not subsampled for other
analyses, as these are robust to differences in sequenc-
ing depth. A single, independent realization of random
subsampling was used for each richness calculation. A
search of the NCBI non-redundant nucleotide database
for related sequences from cultured bacteria was carried
out using the BLASTn web tool [69] searching the non-
redundant nucleotide database with default parameters
and excluding sequences from uncultured organisms.
Statistical analysis
A 0.05 p-value threshold was used to define statistical sig-
nificance, with values below 0.1 considered “suggestive”.
Except where specified, p-values are not corrected for
multiple testing. Due to the risk of violating distributional
assumptions, univariate comparisons between groups
were done using the non-parametric Mann-Whitney U
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test. Differences in multivariate community composi-
tion and dispersion were tested using PERMANOVA
(adonis) and PERMDISP (betadisper) respectively,
both implemented in the vegan package (version 2.4-6
[70]) for the R programming language. Bray-Curtis dis-
similarity was used as the β-diversity index.
Differences in the relative abundance of individual
OTUs were surveyed using the DESeq2 package (ver-
sion 1.18.1 [71]) for R, and fitting a model that included
terms for treatment, sex, site, and the interaction between
treatment and sex. So as to keep valuable distributional
information, all OTUs found in at least two samples
were included in the initial analysis, with p-values calcu-
lated using a Wald test. However, FDR correction using
the Benjamini-Hochberg procedure [72] excluded “rare”
OTUs—those with mean relative abundance less than
0.01% or detected in fewer than 5% of samples—in order
to maintain statistical power by independently reducing
the number of tests.
Interactions between sex and treatment in fecal SCFAs
were assessed for log-transformed concentrations. The
small number of zeros were replaced with half the lowest
detected concentration for that metabolite. Interactions
were tested in an ANOVA that also included terms for
site, sex, and treatment. LASSO regressions of the three
SCFAs and lactate against spike-adjusted OTU abun-
dances were performed using the scikit-learn library for
Python (version 0.18.2 [73]) and log-transformed con-
centrations after adjustment for site, sex, and treatment.
OTUs detected in more than 5% of samples and with
mean abundance greater than 0.01% were included. The
LASSO parameter was determined by randomized 10-fold
cross-validation, optimizing for out-of-bag R2. For each
metabolite we confirmed that OTU abundance informa-
tion improved predictions by testing the Spearman’s rank
correlation between true values and out-of-bag predic-
tions of the best model using a Student’s t-distribution
approximation [74] and a P = 0.05 significance thresh-
old. While this type of regularized regression is primarily
useful for constructing predictive models, and biologi-
cal interpretation can be challenging, non-zero regression
coefficients are suggestive of covariates that are among
themost strongly associated with a response. Proportional
hazards regression was carried out using of the survival
package (version 2.41-3 [75]) for R, and the day of fecal
sampling as the entry time. All sampled mice were dead
at the time of analysis and right-censoring was therefore
not used. Standardized HRs reported for SCFAs are based
on concentrations that have been centered around 0 and
scaled to a standard deviation of 1.
Various experimental data and metadata, including
mouse ages at sampling, pellet weights, and raw HPLC
peak data, are all freely available on GitHub [64], along
with code necessary to reproduce our analyses.
Additional files
Additional file 1: Summary statistics, associations with design parameters
and metabolites, and inferred taxonomic identity of common bacterial
OTUs. Table includes all OTUs with mean relative abundance greater than
0.01% and found in greater than 5% of samples. (XLSX 51 kb)
Additional file 2: Taxonomic analysis of two dominant OTUs. (PDF 58 kb)
Additional file 3: Relative abundance across samples of the most
common unique sequences clustered into (A) OTU-1 and (B) OTU-4. Colors
are assigned to the top four most common unique sequences within each
OTU and all remaining sequences from that OTU are assigned the color
gray. Stacked bars in each position represent individual mice sampled for
this study, and reflect the relative abundance of unique sequences in that
sample. Mice are sorted by sites and then treatments, and finally by the
total abundance of OTU-1. (PDF 49 kb)
Additional file 4: Expanded survival analysis. (PDF 44 kb)
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